燃石医学上涨3.31%，报2.5美元/股，总市值2691.65万美元

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 3.31% on May 6, reaching $2.50 per share, with a total market capitalization of $26.9165 million [1] - As of September 30, 2024, the company's total revenue is projected to be 390 million RMB, a year-on-year decrease of 6.38%, while the net profit attributable to the parent company is expected to be -265 million RMB, reflecting a year-on-year increase of 46.01% [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company's business and R&D directions primarily cover: 1) tumor patient population testing, holding a leading market share in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) multi-cancer early detection [2] - In July 2018, the company received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]